Inogen (INGN) remains unprofitable, with losses widening at a 31.9% annual rate over the past five years. Forecasts show its net profit margin is expected to stay negative for at least three more years. Revenue is projected to grow at 6.2% per year, trailing the US market average of 10.5%. Despite these ongoing losses, the company's stock trades well below estimated fair value. Its price-to-sales ratio of 0.6x is much cheaper than the medical equipment industry average, presenting a mixed scenario for investors weighing value against persistent profitability challenges.

See our full analysis for Inogen.

The next section puts these headline figures up against the dominant market narratives to see whether the numbers confirm or contest the story so far.

See what the community is saying about Inogen

The company’s share price is $7.39, while the current analyst price target is $13.00. This represents a 76% potential upside if analyst projections are realized, illustrating that the market currently values Inogen well below where analysts expect it to go.

According to the analysts' consensus view, a fair value scenario assumes Inogen can grow revenue by 6.5% annually and raise profit margins to the industry average by 2028. This would imply $51.9 million in earnings, an 8.7x PE ratio, and a much higher share price than today.

Consensus narrative notes that this upside depends on Inogen converting challenges in profitability and share count dilution, which is expected to rise 7% per year, into a steady path to earnings improvement.

There is disagreement among analysts, with the highest target at $14.00 and the lowest at $7.00. This shows that opinions are split on whether the company can close the gap to industry profitability.

Get the full picture on Inogen’s risk and reward balance in our latest consensus narrative. ???? Read the full Inogen Consensus Narrative.

Inogen’s profit margin is currently -7.6%, with no profitability expected before 2027. This stands in contrast to the US medical equipment industry average margin of 12.5%.

Analysts' consensus view points to two key reasons for this ongoing gap:

Operational moves such as cutting costs, streamlining the salesforce, and pursuing more business-to-business sales have delivered some improvements in cash flow and adjusted EBITDA, but have not shifted the overall margin picture.

Ongoing regulatory and pricing pressures in core oxygen equipment markets have kept gross margins and profitability under pressure, supporting the consensus caution around Inogen’s ability to match the industry’s stronger margin profile any time soon.

Inogen is trading at a price-to-sales ratio of 0.6x, compared to the industry average of 2.9x and peers at 20.1x. This indicates the stock is considered inexpensive by traditional valuation measures.

Analysts' consensus view points out that this steep discount reflects downside risks as well as lackluster revenue growth. The 6.2% annual revenue forecast falls well short of the 10.5% US market average.

Critics highlight that unless Inogen accelerates revenue growth or delivers margin improvements, this low valuation could persist, despite ongoing innovation in digital integration and new product launches intended to expand the addressable market.

Supporters argue that the current discount is already pricing in profitability doubts, so any execution on margin or top-line drivers could benefit current shareholders.

To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for Inogen on Simply Wall St. Add the company to your watchlist or portfolio so you'll be alerted when the story evolves.

Have a unique angle on the figures? Take just a few minutes to shape that view and add your perspective, then Do it your way

A great starting point for your Inogen research is our analysis highlighting 2 key rewards and 1 important warning sign that could impact your investment decision.

Inogen faces ongoing losses, deeply negative profit margins, and below-average revenue growth. These factors raise concerns about the consistency of its financial performance.

If you’re looking for companies that consistently deliver reliable growth and sustained performance, make the jump to our stable growth stocks screener (2074 results) and discover more dependable investment options right now.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Companies discussed in this article include INGN.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com